In this exclusive interview, Stada Consumer Healthcare's global head Volker Sydow discusses the company's growth ambitions for the business in Europe and further afield. Sydow outlines Stada CHC's local brand hero strategy, an approach which he says sets the firm apart from the competition.
Investing in local, often neglected brands has propelled Stada up the rankings of Europe’s leading OTC players. The Germany-based company believes it can displace Bayer as Europe’s number-three OTC supplier in the not too distant future with its Consumer Healthcare sales on an upward trajectory across the region.
But Stada is not stopping there. “We are very ambitious to become much stronger in European markets where we are...
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
